Amgen AMGN
NASDAQ AMGN
$385.65 +5.87 (+1.55%)
At close: Sep 18, 2026 · 4:00 PM EDT

Amgen (AMGN) Income towards Parent Company (2009 - 2026)

Amgen (AMGN) posted Income towards Parent Company of $2.4 billion for Q2 2026, up 30.57% on a QoQ basis from $1.8 billion in Q1 2026, and up 65.85% year-over-year from $1.4 billion in Q2 2025.

Analysis

Amgen (AMGN) Income towards Parent Company (2009 - 2026) Analysis & Trends

Amgen has reported Income towards Parent Company for 18 years, with the latest figure at $2.4 billion in Q2 2026.

  • On a quarterly basis, Income towards Parent Company rose 65.85% year-over-year to $2.4 billion in Q2 2026; TTM through Jun 2026 was $8.7 billion, a 32.09% increase from a year earlier, with the FY2025 full-year figure at $7.7 billion, up 88.53% from the prior year.
  • Income towards Parent Company was $2.4 billion for Q2 2026 at Amgen, up from $1.8 billion in the prior quarter.
  • The five-year high for Income towards Parent Company was $3.2 billion in Q3 2025, with the low at -$113.0 million in Q1 2024.
  • Average Income towards Parent Company over 5 years is $1.6 billion, with a median of $1.5 billion recorded in 2022.
  • The sharpest annual moves came in 2024 and 2025: Income towards Parent Company tumbled 103.98% in 2024, then soared 1630.97% in 2025.
  • Over 5 years, Income towards Parent Company stood at $1.6 billion in 2022, then sank by 52.54% to $767.0 million in 2023, then decreased by 18.25% to $627.0 million in 2024, then jumped by 112.6% to $1.3 billion in 2025, then surged by 78.17% to $2.4 billion in 2026.
  • The last three Income towards Parent Company figures came in at $2.4 billion (Q2 2026), $1.8 billion (Q1 2026), and $1.3 billion (Q4 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Amgen 208.48 Bn 194.49 Bn 7.24 Bn
2 Gilead Sciences 186.29 Bn 183.02 Bn 6.22 Bn
3 Vertex Pharmaceuticals 128.79 Bn 120.93 Bn 2.84 Bn
4 Regeneron Pharmaceuticals 80.66 Bn 72.67 Bn 3.93 Bn
5 Moderna 61.46 Bn 56.32 Bn 52.00 Mn
6 Argenx Se 61.28 Bn 56.10 Bn 1.37 Bn
7 Alnylam Pharmaceuticals 32.04 Bn 28.73 Bn 992.69 Mn
8 Biogen 31.84 Bn 30.56 Bn 1.96 Bn
9 Roivant Sciences 28.74 Bn 29.43 Bn 1.16 Mn
10 Insmed 26.19 Bn 25.03 Bn 358.27 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 2.38 Bn
Mar 31, 2026 1.82 Bn
Dec 31, 2025 1.33 Bn
Sep 30, 2025 3.22 Bn
Jun 30, 2025 1.43 Bn
Mar 31, 2025 1.73 Bn
Dec 31, 2024 627.00 Mn
Sep 30, 2024 2.83 Bn
Jun 30, 2024 746.00 Mn
Mar 31, 2024 -113.00 Mn
Dec 31, 2023 767.00 Mn
Sep 30, 2023 1.73 Bn
Jun 30, 2023 1.38 Bn
Mar 31, 2023 2.84 Bn
Dec 31, 2022 1.62 Bn
Sep 30, 2022 2.14 Bn
Jun 30, 2022 1.32 Bn
Mar 31, 2022 1.48 Bn
Dec 31, 2021 1.90 Bn
Sep 30, 2021 1.88 Bn